41 results
Page 2 of 3
8-K
EX-99.1
ulhadfr340yugt0
27 Aug 20
Trial Did Not Meet Primary Endpoint Believed to be the Result of BOTOX Not Effectively Permeating the Urothelium
8:01am
8-K
EX-99.1
jq5f 3t9f4e9bi
10 Aug 20
UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments
7:20am
8-K
EX-99.2
lur m6zampm
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
8-K
EX-99.3
6gecxl vlmc7y7ug
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
10-Q
4rqo005
9 May 19
Quarterly report
7:13am
DEF 14A
7tsu152ilmms
26 Apr 19
Definitive proxy
5:00pm
10-K
9wn1h9v0 2l7
28 Feb 19
Annual report
1:08pm
424B5
2zmxe6o5 jt7rv5
25 Jan 19
Prospectus supplement for primary offering
8:01am
424B5
nkp xj4zq96zfd
22 Jan 19
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.2
947c30yc xzcfsbgs
22 Jan 19
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
5:08pm
6-K
EX-99.2
31ue5jp9zu91h sflq5
12 Jul 18
UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors
8:07pm
6-K
EX-99.1
frxf5fhw
25 Apr 18
Current report (foreign)
4:04pm
20-F
a1hd2qio4nsrm0md0qo
15 Mar 18
Annual report (foreign)
12:00am